Table 2.
Characteristics | Positive (n=22) | Negative (n=49) | p |
---|---|---|---|
Age, years, mean (SD) | 68.9 (8.5) | 65.4 (7.8) | 0.096 |
PSA at time of PET/CT, ng/mL, mean (SD) | 64.1 (155.8) | 24.8 (22.9) | 0.086 |
PSA, stratified, ng/mL, n (%) | |||
PSA ≤20 | 12 (54.5) | 28 (57.1) | 0.838 |
PSA >20 | 10 (45.5) | 21 (42.9) | |
cT stage, n (%) | |||
T1 | 5 (22.7) | 29 (59.2) | 0.005 |
T2 | 5 (22.7) | 12 (24.5) | |
T3 | 11 (50.0) | 8 (16.3) | |
T4 | 1 (4.5) | 0 (0.0) | |
cN stage, n (%) | |||
N0 | 9 (40.9) | 43 (87.8) | <0.001 |
N1 | 9 (40.9) | 2 (4.1) | |
Nx | 4 (18.2) | 4 (8.1) | |
Gleason score, n (%) | |||
6 | 1 (4.5) | 2 (4.1) | <0.001 |
7 | 1 (4.5) | 9 (18.4) | |
8 | 1 (4.5) | 26 (53.1) | |
9 | 18 (81.8) | 12 (24.5) | |
10 | 1 (4.5) | 0 (0.0) | |
Proportion of positive cores on biopsy, % (SD) (NA=1) | 74.6 (31.6) | 56.0 (26.2) | 0.013 |
ADT at time of the PET/CT, n (%) (NA=4) | |||
Yes | 5 (22.7) | 4 (8.2) | 0.110 |
No | 17 (77.3) | 41 (83.7) |
ADT: androgen-deprivation therapy; NA: not available; PET/CT: positron-emission tomography-computed tomography; PSA: prostate-specific antigen; SD: standard deviation.